Alto Neuroscience Inc
ANRO3.600USD
-0.510-12.41%
Cierre 09/19, 16:00（ET）Cotizaciones retrasadas 15 min
97.46MCap. mercado
PérdidaP/E TTM
Más Datos de Alto Neuroscience Inc Compañía
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. Through insights derived from the Company’s scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. Its pipeline also includes novel drug candidates in depression, post-traumatic stress disorder (PTSD), and other mental health conditions.
Información de la empresa
Símbolo de cotizaciónANRO
Nombre de la empresaAlto Neuroscience Inc
Fecha de salida a bolsaFeb 02, 2024
Director ejecutivoDr. Amit Etkin, M.D., Ph.D.
Número de empleados76
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 02
Dirección650 Castro Street, Suite 450
CiudadMOUNTAIN VIEW
Bolsa de valoresNYSE Consolidated
PaísUnited States of America
Código postal94041
Teléfono17732555012
Sitio Webhttps://www.altoneuroscience.com/
Símbolo de cotizaciónANRO
Fecha de salida a bolsaFeb 02, 2024
Director ejecutivoDr. Amit Etkin, M.D., Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Amit Etkin, M.D., Ph.D.
Dr. Amit Etkin, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.21M
--
Mr. Christopher Nixon (Chris) Cox
Mr. Christopher Nixon (Chris) Cox
Independent Director
Independent Director
715.65K
--
Mr. Adam Savitz, M.D., Ph.D.
Mr. Adam Savitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.85K
+216.53%
Dr. Ramiro (Raymond) Sanchez, M.D.
Dr. Ramiro (Raymond) Sanchez, M.D.
Independent Director
Independent Director
--
--
Dr. Husseini Manji, M.D.
Dr. Husseini Manji, M.D.
Director
Director
--
--
Mr. Andrew Dreyfus
Mr. Andrew Dreyfus
Independent Director
Independent Director
--
--
Ms. Gwill York
Ms. Gwill York
Independent Director
Independent Director
--
--
Mr. Nicholas (Nick) Smith
Mr. Nicholas (Nick) Smith
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael Hanley
Mr. Michael Hanley
Chief Operating Officer
Chief Operating Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Amit Etkin, M.D., Ph.D.
Dr. Amit Etkin, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.21M
--
Mr. Christopher Nixon (Chris) Cox
Mr. Christopher Nixon (Chris) Cox
Independent Director
Independent Director
715.65K
--
Mr. Adam Savitz, M.D., Ph.D.
Mr. Adam Savitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.85K
+216.53%
Dr. Ramiro (Raymond) Sanchez, M.D.
Dr. Ramiro (Raymond) Sanchez, M.D.
Independent Director
Independent Director
--
--
Dr. Husseini Manji, M.D.
Dr. Husseini Manji, M.D.
Director
Director
--
--
Mr. Andrew Dreyfus
Mr. Andrew Dreyfus
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Alpha Wave Global, LP
13.69%
Armistice Capital LLC
6.00%
Point72 Asset Management, L.P.
4.91%
Etkin (Amit)
4.45%
Franklin Advisers, Inc.
4.29%
Otro
66.65%
Accionistas
Accionistas
Proporción
Alpha Wave Global, LP
13.69%
Armistice Capital LLC
6.00%
Point72 Asset Management, L.P.
4.91%
Etkin (Amit)
4.45%
Franklin Advisers, Inc.
4.29%
Otro
66.65%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
19.52%
Hedge Fund
14.77%
Venture Capital
13.80%
Investment Advisor
13.64%
Individual Investor
7.48%
Research Firm
1.06%
Private Equity
0.92%
Family Office
0.24%
Endowment Fund
0.08%
Otro
28.47%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
175
22.95M
84.78%
-8.18M
2025Q1
171
24.58M
90.79%
-9.93M
2024Q4
154
26.22M
97.22%
-2.96M
2024Q3
131
26.77M
99.31%
+3.33M
2024Q2
102
22.89M
85.38%
+1.53M
2024Q1
71
21.11M
78.78%
+8.14M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Alpha Wave Global, LP
3.71M
13.7%
--
--
Mar 31, 2025
Armistice Capital LLC
1.60M
5.91%
+950.00K
+146.15%
Mar 31, 2025
Point72 Asset Management, L.P.
1.24M
4.58%
-452.10K
-26.72%
Mar 31, 2025
Etkin (Amit)
1.21M
4.45%
--
--
Mar 17, 2025
Franklin Advisers, Inc.
1.16M
4.29%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.22M
4.5%
-11.02K
-0.90%
Mar 31, 2025
Vestal Point Capital, LP
915.00K
3.38%
--
--
Mar 31, 2025
Marshall Wace LLP
852.99K
3.15%
+15.62K
+1.86%
Mar 31, 2025
Cox (Christopher Nixon)
715.65K
2.64%
--
--
Mar 17, 2025
72 Investment Holdings, LLC
667.78K
2.47%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
